| 中文名称 | 氢溴酸西酞 |
|---|---|
| 中文别名 | 喜普妙;1-(3-二甲氨丙基)-1-(4-氟代苯基)-1,3-二氢异苯并呋喃-5-腈,氢溴酸盐;1-[3-(二甲氨基)丙基]-1-(4-氟苯基)-1,3-二氢-5-异苯并呋喃甲腈氢溴酸盐;氢溴酸西肽普兰;氢溴酸西酞;西酞普兰氢溴酸盐;西酞普兰氢溴酸;氢溴酸西酞普兰;氢溴酸西酞普兰 EP标准品;氢溴酸西酞普兰 USP标准品;氢溴酸西酞普兰 标准品;西酞普兰;西酞普兰系统适应性 EP标准品;艾司西酞普兰-a09;氢溴酸氰肽氟苯胺 |
| 英文名称 | Citalopram hydrobromide |
| 英文别名 | 1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobromide;5-ISOBENZOFURANCARBONITRILE, 1,3-DIHYDRO-1-(3-(DIMETHYLAMINO)PROPYL)-1-(4-FLUOROPHENYL)-;CITALOPRAM HBR;(+/-)-CITALOPRAM HYDROBROMIDE;5-isobenzofurancarbonitrile,1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3;Citalopram Hydrobromide Tablets;1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile monohydrobromide;Citalopram (hydrobromide);Citalopram hydrobromide solution;Citalopram, Hydrobromide Salt;(¡À)-Citalopram hydrobromide;(±)-Citalopram hydrobromide;Citalopram;Lu 10-171;Lu 10-171B;1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile hydrobromide;Citalopram hydrobromide;1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile Hydrobromide;Cipramil;Celexa;Seropram;Elopram;Bonitrile HBr;Nitalapram HBr;Prepram HBr;Citalopram hydrobromide [USAN];CPD000326936;Cit;NSC758684;NS00088112;1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile monohydrobromide;MFCD02101306;CITALOPRAM HYDROBROMIDE [USP-RS];I1E9D14F36;Tox21_500258;1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile monohydrobromide;Citalopram hydrobromide, >=98% (HPLC);1-(3-(dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile monohydrobromide;CITALOPRAM HYDROBROMIDE (USP IMPURITY);C20H22BrFN2O;SR-01000003129-2;5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, monohydrobromide;CITALOPRAM HYDROBROMIDE [EP MONOGRAPH];D00822;Citalopram for system suitability, European Pharmacopoeia (EP) Reference Standard;Citalopram hydrobromide, United States Pharmacopeia (USP) Reference Standard;SMR000326936;LU-10-171-B;Citalopram.HBr;Prisdal;CCG-101022;BC164316;Citalopram Hydrobromide, Pharmaceutical Secondary Standard; Certified Reference Material;Citalopram.HBr, 1mg/ml in Methanol;59729-32-7;CCG-213271;NCGC00093717-02;UNII-I1E9D14F36;MLS000860078;MLS000758293;KS-1043;ZD-211;A832439;Q-200865;Lu 10-171 HBr;CS-4735;1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile;hydrobromide;WIHMBLDNRMIGDW-UHFFFAOYSA-N;AC-1595;Pharmakon1600-01504172;HY-B1287;ZD 211;Citalopram hydrobromide [USAN:USP];NCGC00260943-01;FT-0600173;CITALOPRAM HYDROBROMIDE (USP MONOGRAPH);DTXCID60819993;Citalopram (as hydrobromide);SR-01000003129;LP00258;Lupram;Citalopram hydrogen bromide- Bio-X;NSC 758684;Lu 10-171-B;MLS001401376;CITALOPRAM HYDROBROMIDE [HSDB];DTXSID40872344;AKOS005145738;CITALOPRAM HYDROBROMIDE [ORANGE BOOK];NCGC00093717-03;CITALOPRAM HYDROBROMIDE [USP IMPURITY];MLS002222294;1-(3-Dimethylamino-propyl)-1-(4-fluoro-phenyl)-1,3-dihydro-isobenzofuran-5-carbonitrile hydrobromide;CITALOPRAM HYDROBROMIDE (MART.);1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-ben... |
| CAS No. | 59729-32-7 |
| 分子式 | C20H22BrFN2O |
| 分子量 | 405.30 |
4-(2-((2R,3R)-3-(2,5-二氟苯基)-3-羟基-4-(1H-1,2,4-三唑-1-基)丁-2-基)噻唑-4-基)苯甲腈
N-(丁基磺酰基)-O-[4-(4-哌啶基)丁基]-L-酪氨酸盐酸盐一水合物
2-(4-(1-羟基-4-(4-(羟基二苯基甲基)哌啶-1-基)丁基)苯基)-2-甲基丙酸
7-环戊基-N,N-二甲基-2-((5-(哌嗪-1-基)吡啶-2-基)氨基)-7H-吡咯并[2,3-d]嘧啶-6-甲酰胺
(1-((2R,3R,4S,5R)-3,4-二羟基-5-甲基四氢呋喃-2-基)-5-氟-2-氧代-1,2-二氢嘧啶-4-基)氨基甲酸戊酯
((3S,5R)-5-((1H-1,2,4-三唑-1-基)甲基)-5-(2,4-二氟苯基)四氢呋喃-3-基)甲基 4-甲基苯磺酸酯
N-(3-氯-4-氟苯基)-7-甲氧基-6-(3-吗啉-4-丙氧基)喹唑啉-4-胺
(6R,7R)-3-甲基-7-[(R)-2-氨基-2-苯乙酰氨基]-8-氧-5-硫杂-1-双环[4.2.0]辛-2-烯-2-甲酸
(2R,3S,5S)-3-苄氧基-5-[2-[[(4-甲氧基苯基)二苯基甲基]氨基]-6-苄氧基-9H-嘌呤-9-基]-2-苄氧基甲基环戊醇
(2R,3R,4S,5R)-2-(4-氨基吡咯并[2,1-F][1,2,4]三嗪-7-基)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-甲腈
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。
CopyRight @2025 广东元丰化学试剂有限公司 版权所有 | 隐私政策 条款及条件 | 粤ICP备2025403430号-1
技术支持:库价化学